2 results
Approved WMOWill not start
To improve overall survival of patients with a early-stage high grade uterine leiomyosarcoma.
Approved WMOCompleted
PrimaryTo compare progression-free survival (PFS) between tivozanib in combination with mFOLFOX6 and bevacizumab in combination withmFOLFOX6 based on investigator radiological tumor assessmentSecondary• Progression Free Survival (PFS) based on…